金催化原位杂交：一种用于检测Her-2/neu基因扩增的明场自动金相法，可替代荧光原位杂交。
Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification.
作者信息
Tubbs Raymond, Pettay James, Skacel Marek, Powell Richard, Stoler Mark, Roche Patrick, Hainfeld James
机构信息
Department of Anatomic Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195-5131, USA.
出版信息
Am J Pathol. 2002 May;160(5):1589-95. doi: 10.1016/S0002-9440(10)61106-6.
Abstract
Fluorescence in situ hybridization (FISH) represents an excellent method for profiling gene amplification in situ, but correlation with tissue morphology is difficult because of dark-field visualization. Validation of a bright-field assay for assessment of HER-2/neu gene amplification was investigated. Streptavidin-Nanogold was used to generate bright-field gene copy signals using GoldEnhance gold-based autometallography, catalyzed reported deposition, and a biotin-labeled probe. One hundred cases of invasive breast carcinoma were evaluated for which FISH gene copy results, and mRNA and oncoprotein gene expression, were known. Autometallographic signals were qualitatively evaluable without the use of oil immersion microscopy. Results correlated well with indirect and direct label FISH. Autometallographic gold-based in situ hybridization represents a promising bright-field assay for the assessment of HER-2/neu gene amplification.
摘要
荧光原位杂交（FISH）是一种用于原位分析基因扩增的优秀方法，但由于暗视野可视化，与组织形态学的相关性很难建立。我们对一种用于评估HER-2/neu基因扩增的明视野检测方法进行了验证研究。使用链霉亲和素-纳米金，通过金增强型基于金的自动金相法、催化报告沉积法和生物素标记探针来产生明视野基因拷贝信号。对100例浸润性乳腺癌病例进行了评估，这些病例的FISH基因拷贝结果、mRNA和癌蛋白基因表达情况已知。无需使用油浸显微镜即可对自动金相信号进行定性评估。结果与间接和直接标记FISH的结果相关性良好。基于金的自动金相原位杂交是一种很有前景的用于评估HER-2/neu基因扩增的明视野检测方法。
相似文献
1
Gold-facilitated in situ hybridization: a bright-field autometallographic alternative to fluorescence in situ hybridization for detection of Her-2/neu gene amplification.
Am J Pathol. 2002 May;160(5):1589-95. doi: 10.1016/S0002-9440(10)61106-6.
2
Interobserver interpretative reproducibility of GOLDFISH, a first generation gold-facilitated autometallographic bright field in situ hybridization assay for HER-2/neu amplification in invasive mammary carcinoma.
Am J Surg Pathol. 2002 Jul;26(7):908-13. doi: 10.1097/00000478-200207000-00009.
3
Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH): a fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression.
J Mol Diagn. 2000 May;2(2):78-83. doi: 10.1016/S1525-1578(10)60620-4.
4
Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH).
Am J Surg Pathol. 2010 Aug;34(8):1180-5. doi: 10.1097/PAS.0b013e3181e70e15.
5
[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26.
6
HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: direct comparison with companion tissue sections.
Diagn Cytopathol. 2000 Nov;23(5):299-302. doi: 10.1002/1097-0339(200011)23:5<299::aid-dc2>3.0.co;2-x.
7
Her-2/neu Oncogene Amplification by Fluorescence In Situ Hybridization and Protein Overexpression on Immunohistochemistry in Breast Cancer.
J Coll Physicians Surg Pak. 2018 Aug;28(8):581-585. doi: 10.29271/jcpsp.2018.08.581.
8
Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
Int J Surg Pathol. 2006 Oct;14(4):279-84. doi: 10.1177/1066896906293055.
9
10
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
Am J Pathol. 2000 Nov;157(5):1467-72. doi: 10.1016/S0002-9440(10)64785-2.
引用本文的文献
1
FICTION Technique-A Candidate for the Assessment of HER2 Status in Breast Invasive Carcinomas.
Medicina (Kaunas). 2025 Jun 11;61(6):1069. doi: 10.3390/medicina61061069.
2
Testing for HER2 in Breast Cancer: A Continuing Evolution.
Patholog Res Int. 2010 Dec 6;2011:903202. doi: 10.4061/2011/903202.
3
Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.
J Clin Pathol. 2010 Mar;63(3):210-9. doi: 10.1136/jcp.2009.062760.
4
Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH).
Diagn Pathol. 2008 Oct 22;3:41. doi: 10.1186/1746-1596-3-41.
5
Genotyping of phenotypically defined cells in neoplasia: enhanced immunoFISH via tyramide signal amplification (TSA) segregates immunophenotypically-defined cell populations for gated genotyping.
J Mol Histol. 2007 May;38(2):129-34. doi: 10.1007/s10735-006-9074-1. Epub 2007 Jan 5.
6
Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer.
J Mol Histol. 2004 Aug;35(6):647-53. doi: 10.1007/s10735-004-2186-6.
7
Novel bright field molecular morphology methods for detection of HER2 gene amplification.
J Mol Histol. 2004 Aug;35(6):589-94. doi: 10.1007/s10735-004-2191-9.
8
Guidelines for HER2 testing in the UK.
J Clin Pathol. 2004 Mar;57(3):241-2. doi: 10.1136/jcp.2003.009308.
本文引用的文献
1
Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.
J Clin Oncol. 2001 May 15;19(10):2714-21. doi: 10.1200/JCO.2001.19.10.2714.
2
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
J Clin Oncol. 2001 May 15;19(10):2587-95. doi: 10.1200/JCO.2001.19.10.2587.
3
Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry.
Am J Clin Pathol. 2001 Apr;115(4):504-11. doi: 10.1309/VP4W-5C55-7M09-6TX3.
4
Concomitant oncoprotein detection with fluorescence in situ hybridization (CODFISH): a fluorescence-based assay enabling simultaneous visualization of gene amplification and encoded protein expression.
J Mol Diagn. 2000 May;2(2):78-83. doi: 10.1016/S1525-1578(10)60620-4.
5
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
N Engl J Med. 2001 Mar 15;344(11):783-92. doi: 10.1056/NEJM200103153441101.
6
Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization.
J Clin Oncol. 2001 Jan 15;19(2):354-63. doi: 10.1200/JCO.2001.19.2.354.
7
Clinical relevance of HPV 16/18 testing methods in cervical squamous cell carcinoma.
Appl Immunohistochem Mol Morphol. 2000 Dec;8(4):300-9.
8
Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use.
Histopathology. 2000 Nov;37(5):411-9. doi: 10.1046/j.1365-2559.2000.00984.x.
9
Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
Mod Pathol. 2000 Nov;13(11):1238-43. doi: 10.1038/modpathol.3880228.
10
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
Am J Pathol. 2000 Nov;157(5):1467-72. doi: 10.1016/S0002-9440(10)64785-2.
Zotero 插件